Docetaxel albumin bound

CSPC Pharmaceutical Group Limited (HKEX: 01093) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to both docetaxel for injection (albumin-bound) (HB1801) and anbenitamab (KN026), a HER2-targeted bispecific antibody, for use in combination as first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults. The designation accelerates regulatory review and provides more intensive NMPA guidance during development — and arrives five weeks after the Phase III Healer trial (KN026-003) reported that the combination met its primary endpoint of progression-free survival (PFS) against the current standard of care. Anbenitamab simultaneously binds two non-overlapping epitopes on the HER2 receptor, enabling dual-domain signal blockade through a single molecule. This mechanism is mechanistically distinct from the two-antibody approach of the trastuzumab-pertuzumab combination used in the standard THP regimen (trastuzumab plus pertuzumab plus docetaxel). Through antibody-induced receptor clustering, anbenitamab also enhances antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity while promoting HER2 receptor downregulation. HB1801 encapsulates docetaxel in human serum albumin, eliminating the polysorbate 80 and ethanol solvents required by conventional docetaxel formulations, removing the need for steroid premedication and permitting higher-concentration administration. The Healer trial (KN026-003) is a randomized, controlled, open-label, multicenter Phase III study designed to enroll approximately 880 patients with HER2-positive advanced breast cancer, assigned 1:1 to anbenitamab plus HB1801 or the THP regimen. The primary endpoint is PFS as assessed by a Blinded Independent Review Committee (BIRC). In June 2026, the Independent Data Monitoring Committee determined that the combination statistically significantly prolonged PFS and reduced the risk of disease progression or death compared with THP, with a trend toward an overall survival benefit. No specific hazard ratio, median PFS figures, or p-values have been disclosed; detailed data are expected at an upcoming international academic conference. The neoadjuvant Phase III trial (Neo-Healer, KN026-004) has provided the most granular publicly available efficacy data for this combination. Presented as a late-breaking oral abstract at the 2026 American Society of Clinical Oncology Annual Meeting, the trial enrolled 521 patients with early or locally advanced HER2-positive breast cancer and randomized them 1:1 to anbenitamab plus HB1801 ± carboplatin or THP ± carboplatin for six cycles. The BIRC-assessed total pathological complete response (tpCR) rate was 62.4% (95% CI: 56.2–68.2) in the experimental arm versus 51.2% (95% CI: 44.9–57.4) in the control arm (one-sided p \= 0.0036). The Breakthrough Therapy Designation for the first-line advanced setting directly supports the companies’ stated plan to submit a New Drug Application (NDA) to the NMPA for this indication in the near future. Under China’s Breakthrough Therapy pathway, designated products receive priority scheduling, more frequent interactions with the NMPA’s Center for Drug Evaluation, and eligibility for rolling review. Anbenitamab had previously received NMPA Breakthrough Therapy Designation for HER2-positive advanced gastric cancer following failure of first-line treatment, and that program culminated in marketing authorization granted in May 2026. CSPC and its co-development partner, China-based Alphamab Oncology (HKEX: 09966), have positioned the HB1801 plus anbenitamab combination across the full HER2-positive breast cancer disease continuum. Phase III trials now cover neoadjuvant (Neo-Healer, primary endpoint met), adjuvant (ongoing), and first-line advanced (Healer, primary endpoint met) settings, with the Breakthrough Therapy Designation applying to the advanced first-line indication. The NDA submission for the neoadjuvant breast cancer indication is also described as forthcoming. Anbenitamab holds only an FDA Orphan Drug Designation for HER2-positive gastric cancer and has not entered US registration-enabling trials for breast cancer. The next material milestone is the public presentation of full Healer (KN026-003) efficacy and safety data, including the PFS hazard ratio, median PFS, and subgroup analyses, at an international academic conference. That dataset will determine whether the magnitude of PFS benefit over THP supports the regulatory and commercial case for the combination in first-line advanced HER2-positive breast cancer, and will inform the scope and timing of the planned NDA submission to the NMPA. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.